

17th International Congress on **LUNG TRANSPLANTATION**

Paris, September 10-11, 2026

Program

Union Internationale
des Chemins de Fer
16 rue Jean Rey - Paris XV

www.lungtransplantation.org



FOCH LUNG TRANSPLANT GROUP

Endorsed by





Dear Colleagues

We are pleased to welcome you to the 17th International Congress on Lung Transplantation, which is held in Paris on September 10-11, 2026.

The scientific program includes new subjects in addition to classic topics, presented by eminent leaders in the field of transplantation.

Our hope is that numerous lectures and debates will be fruitful and have a positive impact on the future of each participant.

Welcome in the beautiful city of Paris!

Best regards,

Antoine ROUX, Edouard SAGE
for the Organizing Committee

Presidents of the congress

Laurie Snyder (Durham, USA)
Laurens Ceulemans (Leuven, Belgium)

Local Organizing Committee

Honorary Presidents

Alain Bisson, Marc Stern

Presidents

Edouard Sage, Antoine Roux

Members

Olivier Brugière, Alain Chapelier,
Dominique Grenet, Abdul Hamid,
Morgan Le Guen, Sandra de Miranda,
François Parquin, Clément Picard,
Benjamin Zuber

International Scientific Committee

A. d'Armini (I)
P. Corris (UK)
R.D. Davis (USA)
T. Egan (USA)
M. Hertz (USA)
S. Keshavjee (CND)
W. Klepetko (A)
D. Levine (USA)
S. Lindstedt (SWE)
T. Martinu (CA)
J.F. Mornex (F)
H. Reichenspurner (D)
G. Snell (AUS)
A. Varela (SP)



Scientific Information

* If you are a chairperson

You must be in your session room 10 minutes prior the beginning of the session.

Make sure that all speakers observe timing.

Participants should not speak without permission.

They should first clearly state their name, institution and country.

* If you are a speaker

Locate your session room in due time.

Speakers must go to the preview room and turn in their slides or computer-assisted presentations that will be handed out to the session room.

Personal laptops cannot be used for the presentations.

In the session room, strictly follow instructions from the chairperson, in particular those regarding the timing of your presentation.

* Congress Dinner Upon reservation

The Congress Dinner will take place on the boat "Le Capitaine Fracasse" on thursday, 8.00 pm.

Le Capitaine Fracasse

Port de Javel Haut, 75015 Paris

Price per person: 80 Euros

7:30 p.m. - Boarding on the boat

8:00 p.m. - Departure of the boat

RER station: Line C, Javel

Metro station: Line 10, Javel - André Citroën

* Technical Exhibition

The technical exhibit is located close to the conference rooms. Please plan to visit the exhibit regularly, and especially during the breaks.

Exhibitors:	CARE DX	TAKEDA
	GRIFOLS	THERAKOS
	MICROGEN DX	XVIVO
	PARAGONIX	

* Administrative Secretariat

Office hours during the congress:

• **Thursday 10:**

7:30 - 18:30

• **Friday 11:**

7:30 - 16:30

After the congress:

VBC - Lung Transplantation

223 avenue Emile Counord

33300 Bordeaux (France)

Phone: +33 (0)6 27 48 21 24

e-mail: c.deplagne@vbc-congres.fr

Website: www.vbc-congres.fr

General Information

* Badges

For security and regulation reasons, all participants will be required to wear their badge at all times throughout the Congress.

* Certificate of attendance

A certificate of attendance for registered participants will be available after the congress, from September 14, on the congress website.

* Insurance

The Organizers do not accept responsibility for individual medical, travel or personal insurance. Delegates are strongly advised to take out their own personal insurance policy.

Secretariats

* Scientific Secretariat

Pr Antoine ROUX et Pr Edouard SAGE

Hôpital Foch - Service de Pneumologie

40 rue Worth - 92151 Suresnes (France)

Phone: +33 (0)1 46 25 22 44

e-mails: a.roux@hopital-foch.com

e.sage@hopital-foch.com



Program Overview

Thursday 10	Room Louis Armand	Room Friedrich List
8:30 → 9:00	Welcome	
9:00 → 9:30	Big Picture 1 Preservation as a determinant of outcome	
9:30 → 11:00	New frontiers in indications - Focus on recipient	Infectious diseases
11:00 → 11:20	Break	
11:20 → 12:15	Big Picture 2 Building for the future	
12:15 → 13:15	Academic lunch symposium Therakos	
13:15 → 13:45	Break	
13:45 → 15:45	Donor, graft allocation and perioperative strategies	Graft dysfunction – New definitions (alphabet soup)
15:45 → 16:00	Break	
16:00 → 18:00	Lung preservation and EVLP	Graft dysfunction – Basics of physiopathology / Biomarkers
18:00 → 19:00	Poster session with wine and cheese	
Friday 11	Room Louis Armand	Room Friedrich List
9:00 → 9:30	Big Picture 3 - AI in transplantation Session supported by sanofi	
9:30 → 11:15	Perioperative strategies and PGD	Graft dysfunction – Molecular and clinical practice, risk assessment Session supported by sanofi
11:15 → 11:35	Break	
11:35 → 13:05	DCD	Taking a lead from other diseases... and translating treatments before and after lung Tx
13:10 → 14:10	Academic lunch symposium sanofi	
14:10 → 14:40	Break	
14:40 → 16:20	Next future	
16:20 → 16:30	Poster award - Best abstract award	
16:30 → 16:40	Meeting conclusion	



Scan this QR code to consult
and/or upload the Book of Abstracts



8:30 → 9:00

Room Louis Armand

Welcome

Introduction

Presidents of the Congress:

Laurie Snyder (Durham, USA),

Laurens Ceulemans (Leuven, Belgium)

Presidents of the Local Organizing Committee:

Antoine Roux, Edouard Sage (Suresnes, France)

9:00 → 9:30

Room Louis Armand

Big Picture 1

Chairs: **Sandra Lindstedt (Lund, Sweden)**

Edouard Sage (Suresnes, France)

Preservation as a determinant of outcome

Clemens Aigner (Vienna, Austria)

25 min + 5 min discussion

9:30 → 11:00

Room Louis Armand

New frontiers in indications - Focus on recipient

Chairs: **Alberto Benazzo (Vienna, Austria)**

Kieran Halloran (Edmonton, Canada)

Invited Speaker: 12 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

09:30 **Transplanting at the extremes: elderly and frail recipients**

Marie Budev (Cleveland, USA)

09:47

O1 - Is Lung transplant landscape changing? A Temporal analysis of changing indications and outcomes in lung transplantation over last decade - Royal Papworth Hospital experience
Maksym Kovzel (Cambridge, UK)

09:54

Thinking outside the lung: systemic disease and considerations for lung transplant
Jérôme Le Pavec (Paris, France)

10:11

O2 - Towards a paradigm shift in cystic fibrosis lung transplantation: The emerging role of retransplantation
Maxine Huriet (Suresnes, France)

10:18

Short telomere syndrome and lung transplant: biology and outcomes
Andrew Courtwright (Utah, USA)

10:35

O3 - Combined lung–liver transplantation in the United States: National trends and single-center experience
Mindaugas Rackauskas (Gainesville, USA)

10:42

How to reach 100% of transplantable candidates
Jasleen Kukreja (San Francisco, USA)



9:30 → 11:00

Room Friedrich List

Infectious disease

Chairs: **Letizia Morlacchi (Milan, Italy)**
Mace Schuurmans (Zurich, Switzerland)

Invited Speaker: 12 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

09:30 **HIV and lung transplant**
Cameron Wolfe (Durham, USA)

09:47 **O4 - Real-world CMV hyperimmuno-
globulin prophylaxis in heart and lung
transplantation: One-year interim results
from a prospective multicenter study**
Markus Barten (Hamburg, Germany)

09:54 **On the horizon- Increasing rates of
MDR organisms and mollicutes**
Alessandra Mularoni (Palermo, Italy)

10:11 **O5 - Identification of bacterial species
early after lung transplant that predict
acute cellular rejection using a novel
sequencing approach**
Brian Keller (Boston, USA)

10:18 **Invasive molds/fungus and emerging
resistance- Focus on new species, new
treatments, what is in the pipeline/
nearing approval, surgical management
(post transplant)**
Fanny Lanternier (Paris, France)

10:35 **Novel molecular diagnostics for
detection of infections and the
implications for clinical care**
Laurie Snyder (Durham, USA)

10:52 **O6 - Improved sensitivity for respiratory
pathogen detection in bronchoalveolar
lavage from lung transplant recipients
using targeted next-generation
sequencing**
**Elena Friedmann (Lausanne,
Switzerland)**

11:00 → 11:20

Break

11:20 → 12:15

Room Louis Armand

Big Picture 2 Building for the future

Chairs: **Brian Keller (Boston, USA)**
Lorenzo Rosso (Milan, Italy)

11:20 **Building a lung transplant program -
Research, clinical, education - Medical
and surgical perspectives**
Tereza Martinu (Toronto, Canada)

11:35 **Pediatric perspective in 2026**
Christian Benden (Boston, USA)

11:50 **LifeLUNG European research
consortium on genetic modulation**
Laurens Ceulemans (Leuven, Belgium)

12:05 **Discussion**



12:15 → 13:15

Room Louis Armand

Academic lunch symposium



Chair: Jonathan Messika (Suresnes, France)

12:15

Welcome

Jonathan Messika (Suresnes, France)

12:20

Expanding the role of ECP in SOT:
From prevention strategies to ABMR
management

Alberto Benazzo (Vienna, Austria)

12:35

Managing CLAD with ECP: Clinical
evidence and real-world experience

Adrien Tissot (Nantes, France)

12:50

Understanding how ECP works:
Translating mechanisms into clinical
benefit

James Hutchinson (Regensburg,
Germany)

13:05

Q&A session

13:15 → 13:45

Break

13:45 → 15:45

Room Louis Armand

Donor, graft allocation and perioperative strategies

Chairs: Clemens Aigner (Vienna, Austria)
Mauricio Villavicencio (Rochester, USA)

13:45

Invited Speaker: 12 min + 5 min discussion

13:45

Selected Abstract: 5 min + 2 min discussion

13:45

Moderated cases presentations

25 min + 5 min discussion

Moderator:

Debbie Levine (Palo Alto, USA)

Discussants:

Laurens Ceulemans (Leuven, Belgium)

Marcelo Cypel (Toronto, Canada)

Jasleen Kukreja (San Francisco, USA)

14:15

07 - Donors with prolonged mechanical
ventilation are good donors

Houda Zelloufi (Marseille, France)

14:22

08 - Single vs bilateral lung
transplantation in elderly patients:

Revisiting the best approach

Letizia Corinna Morlacchi (Milan, Italy)

14:29

09 - Investigating the impact of donor
brain death duration on outcomes after
lung transplant

Alice Coates (Newcastle, UK)

14:36

010 - Ex vivo CRISPR gene editing of
donor lungs using virus-like particles
during rat lung perfusion

Phéline Kortleven (Leuven, Belgium)



14:43 Allocation systems and regional differences: an international perspective
Hiroshi Date (Durham, USA)

15:00 **O11** - Extent and determinants of differential access to lung transplantation: A nationwide study of theoretically eligible patients
Pauline Pradère (Le Plessis Robinson, France)

15:07 Robotic lung transplant
Stephanie Chang (New York, USA)

15:24 Donor and recipient infections and the role of surgery
Robin Vos (Leuven, Belgium)

13:45 → 15:45

Room Friedrich List

Graft dysfunction – New definitions (alphabet soup)

Chairs: **Stephen Juvet (Toronto, Canada)**
Sam Weigt (Los Angeles, USA)

Invited Speaker: 15 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

14:45 ALAD: now that we have a definition, how should we be using it?
Ciara Shaver (Nashville, USA)

14:05 **O12 & O13 - Joint abstract presentations**
O12 - Alloimmune acute lung allograft dysfunction: incidence, clinical course, treatment response, and long-term graft impact

O13 - ALAD landscape: incidence, severity, etiology, and outcome associations in a single center comprehensive post-transplant cohort
Zisis Balmpouzis (Lausanne, Switzerland)

10 min + 3 min discussion

14:18 **O14** - Phenotype matters: Acute lung allograft dysfunction and outcomes after lung transplantation
Sophie Auner (Vienna, Austria)

14:25 **O15** - Serum proteomic profiling of acute lung allograft dysfunction identifies candidate biomarkers: A pilot discovery study
Abrar Alhamoudi (Riyadh, Saudi Arabia)

14:32 **O16** - Clinical and molecular profiling of pediatric acute lung allograft dysfunction reveals fibrogenic programs in immunologic and non-immunologic subtypes
Don Hayes (Cincinnati, USA)

14:39 BLAD: now that we have a definition, how should we be using it?
Jens Gottlieb (Hannover, Germany)

14:59 **O17** - Comparing phenotypes of baseline lung allograft dysfunction after lung transplantation
Stefan Schwarz (Vienna, Austria)



15:06 **O18** - Defining baseline lung allograft dysfunction: Evaluating percentage predicted and lower limits of normal FEV1 values using global lung function initiative reference equations for prognostication after lung transplantation

Andrea Zajacova (Leuven, Belgium)

15:13 Applying ISHLT definitions to real world data

Megan Neely (Durham, USA)

Presentation: Laurie Snyder (Durham, USA)

20 min + 5 min discussion

15:45 → 16:00

Break

16:00 → 18:00

Room Louis Armand

Lung preservation and EVLP

Chairs: **Stephanie Chang (New York, USA)**
Britton Donato (Grand Rapids, USA)

Invited Speaker: 15 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

16:00 Regional perspectives and controversies: Different models and the way forward
Konrad Hoetzenecker (Nashville, USA)

16:20 Controlled hypothermic storage
Marcelo Cypel (Toronto, Canada)

16:40 EVLP 2026 for assessment and preservation
Edouard Sage (Suresnes, France)

17:00 **O19** - Controlled hypothermic storage results in significantly lower risk for death or hospital readmission within one year after lung transplantation in a single high-volume center

Annalisa Barbarossa (Heverlee, Belgium)

17:07 **O20** - Stress index monitoring during clinical ex vivo lung perfusion: First small cohort analysis and translational perspective for SI-guided ventilation
Jakob Homola (Wien, Austria)

17:14 EVLP 2026 for modulatory strategies
Matthew Hartwig (Durham, USA)

17:34 **O21** - Immune-silenced mesenchymal stromal cell therapy supports recovery of aspiration-injured donor lungs during ex vivo lung perfusion and transplantation
Franziska Olm (Lund, Sweden)

17:41 **O22** - Safe and efficient non-viral lipid nanoparticle (LNP)-mediated mRNA delivery in a rat ex vivo lung perfusion model
Annalisa Barbarossa (Heverlee, Belgium)

17:48 **O23** - Thirteen years of single-centre experience with Ex Vivo Lung Perfusion: Expanding the donor pool and improving outcomes in lung transplantation
Chloé Mimimi (Suresnes, France)



16:00 → 18:00

Room Friedrich List

Graft dysfunction – Basics of physiopathology/biomarkers

Chairs: John McDyer (Pittsburgh, USA)
Tereza Martinu (Toronto, Canada)

Invited Speaker: 12 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

16:00 Innate immune mechanisms of graft
dysfunction
Stephen Juvet (Toronto, Canada)

16:17 **O24** - *Pseudomonas aeruginosa*
colonization drives epithelial-
mesenchymal transition in chronic lung
allograft dysfunction via macrophage-
derived THBS-1
Zitao Wang (Wuxi, China)

16:24 **O25** - Phage therapy induces endotoxin
tolerance in resident macrophages to
reduce THBS-1 and improve CLAD
Zitao Wang (Wuxi, China)

16:31 Role of complement in lung transplant
rejection/dysfunction
Hrshikesh Kulkarni (Los Angeles, USA)

16:48 **O26** - Early secretory phospholipase
A2 type IIA (sPLA2-IIA) in the allograft
proximal airways is associated with
lung dyshomeostasis: A prospective
multicenter study
Elena Floris (New York, USA)

16:55 **O27** - Early leukotriene B4 in lung
allograft bronchoalveolar lavage is
associated with injurious events and
development of chronic lung allograft
dysfunction
Elena Floris (New York, USA)

17:02 cfDNA in lung transplant
Sam Weigt (Los Angeles, USA)

17:19 **O28** - First genome-wide association
study of chronic lung allograft
dysfunction discovers two novel loci
Sophie Limou (Nantes, France)

17:26 **O29** - Predicting CLAD: early post-
transplant BAL microRNAs reveal future
allograft outcomes
Valentina Vaira (Milan, Italy)

17:33 **O30** - CLAD-EV-induced metabolic
remodeling in primary bronchial epithelial
and pulmonary endothelial cells
Valentina Vaira (Milan, Italy)

17:40 CT-based markers and the role of
photocounting for Graft dysfunction
prediction or diagnosis
Adriana Dubbeldam (Leuven, Belgium)

18:00 → 19:00

Poster session with wine and cheese

Dinner on the Boat Capitaine Fracasse

Upon reservation

19:30 - Boarding on the boat

20:00 - Departure of the boat



9:00 → 9:30

Room Louis Armand

Session supported by **sanofi**

Big Picture 3

Chairs: Jason Christie (Philadelphia, USA)
Matthew Hartwig (Durham, USA)

AI in transplantation

Alexandre Loupy (Suresnes, France)

25 min + 5 min discussion

9:30 → 11:15

Room Louis Armand

Perioperative strategies and PGD

Chairs: Geoffrey Brioude (Marseille, France)
Marcelo Cypel (Toronto, Canada)

Invited Speaker: 15 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

09:30 Is PGD still an actual challenge?
Perioperative prevention and
management
Mauricio Villavicencio (Rochester, USA)

09:50 Does PGD matter in the long run?
Is it time for a new definition?
Michaela Anderson (Philadelphia, USA)

10:10 Lung IRI and PGD at the molecular level
Balın Özsoy (Leuven, Belgium)

10:30 Update on ECLS trials
Gabe Loor (Houston, USA)

10:50

O31 - Non-vascularized rectus fascia
allotransplantation as innovative tool
for complex chest wall stabilization after
lung transplantation
Margherita Brivio (Leuven, Belgium)

10:57

O32 - Sternal closure technique
determines outcome after clamshell
incision for bilateral lung transplantation:
A multicenter study
Margherita Brivio (Leuven, Belgium)

11:04

O33 - Failure-to-rescue in lung
transplant recipients developing
bronchial dehiscence or fistula
Jan Van Slambrouck (Leuven, Belgium)

9:35 → 11:15

Room Friedrich List

Session supported by **sanofi**

Graft dysfunction - Molecular and clinical practice / risk assessment

Chairs: Michael Perch (Copenhagen, Denmark)
Ciara Shaver (Nashville, USA)

Invited Speaker: 12 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

09:35 Molecular landscape of acute cellular
rejection
Kieran Halloran (Edmonton, Canada)

09:52 AMR: now that we have a definition,
how should we be using it?
Debbie Levine (Palo Alto, USA)



10:09 **O34** - Beyond MFI: Urea-based assessment of HLA antibody avidity in solid-phase assays
Daniela Koren (Vienna, Austria)

10:16 **O35** - Intra-graft anti-HLA antibodies in lung transplant cryobiopsies identify a humoral activation phenotype in acute cellular rejection
Andrea Zajacova (Leuven, Belgium)

10:23 Not just immunosuppression, what is on the horizon with pharmacological treatments?
Haifa Lyster (Harefield, UK)

10:40 **O36** - Monitoring the impact of eosinophil polynuclear cells in chronic lung allograft rejection
Aurélia Lebeau (Suresnes, France)

10:47 Risk profiling and adjusting therapy
Peter Jaksch (Wien, Austria)

11:04 **O37** - Beyond blood: The two faces of allograft injury - Distinct BAL and plasma cfDNA signatures after lung transplantation
Peter Jaksch (Wien, Austria)

11:15 → 11:35

Break

11:35 → 13:05

Room Louis Armand

DCD

Chairs: **Jasleen Kukreja (San Francisco, USA)**
Alessandro Palecchi (Milan, Italy)

Invited Speaker: 15 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

11:35 DCD II: evolving practices and protocols
Lorenzo Rosso (Milan, Italy)

11:55 DCD III: the new standard or hidden threats?
James Yun (Cleveland, USA)

12:15 NRP: impact on the lung, harmless or not?
Jose-Luis Campo-Canaveral (Madrid, Spain)

12:35 DCD: direct procurement after all...
Pablo Sanchez (Chicago, USA)

12:55 **O38** - Lung transplantation after normothermic abdominal regional perfusion (LUNAR) - The Dutch experience
Annelot Muntinga (Rotterdam, The Netherlands)



11:35 → 13:05

Room Friedrich List

Taking a lead from other diseases... and translating treatments before and after lung transplant

Chairs: Rayid Abdulkawi (Riyadh, Saudi Arabia)
Laurie Snyder (Durham, USA)

Invited Speaker: 15 min + 5 min discussion

Selected Abstract: 5 min + 2 min discussion

11:35 From atlas to therapy: Bridging pulmonary GVHD and CLAD
Marta Zapata (Barcelona, Spain)

11:55 Th2 inflammation targets: from general pneumology to lung transplantation
Colas Tcherakian (Suresnes, France)

12:15 **O39** - Prognosis of lung transplantation for alpha1-antitrypsin deficiency related emphysema depending on postoperative augmentation therapy strategy (ProLungDAAT)
Elisa Chen (Paris, France)

12:22 From SIRS to precision care: Rethinking renal dysfunction in lung transplantation
Greet de Vlieger (Leuven, Belgium)
12 min + 3 min discussion

12:39 **O40** - Secondary thrombotic microangiopathy following lung transplantation: A multicenter European cohort study
Zsofia Rosselli (Zürich, Switzerland)

12:46 Discussion

13:10 → 14:10

Room Louis Armand

Academic lunch symposium sanofi

Chairs: Michaela Anderson (Philadelphia, USA)
Merel Hellemons (Rotterdam, The Netherlands)

13:10 Heterogeneity of CLAD at molecular and clinical Level
John McDyer, (Pittsburgh, USA)

13:30 Methodology to consider with CLAD approach: prevention and treatment
Jason Christie (Philadelphia, USA)

13:45 Real world experience with CLAD trials
Andrew Fisher (Newcastle, UK)

14:00 Discussion

14:10 → 14:40

Break



Scan this QR code to consult
and/or upload the Book of Abstracts



14:40 → 16:20

Room Louis Armand

Next future

Chairs: Laurens Ceulemans (Leuven, Belgium)
Laurie Snyder (Durham, USA)
Antoine Roux, Edouard Sage (Suresnes, France)

Invited Speaker: 20 min + 5 min discussion

14:40 Car-T cells, bi specific Ab and anti CD38 molecules strategies in solid organ transplantation
Julien Zuber (Paris, France)

15:05 Xenotransplantation
Aurelie Sannier (Paris, France)

15:30 Mitochondrial transplantation
Sandra Lindstedt (Lund, Sweden)

15:50 Breathing new heights:
The Aconcagua story
Clemens Aigner (Vienna, Austria)
Peter Jaksch (Wien, Austria)
Patient: Helmut Steigersdorf (Austria)

16:20 → 16:30

Room Louis Armand

Poster award Best abstract award

16:30 → 16:40

Room Louis Armand

Meeting conclusion

16:40

End of the meeting

AI in solid organ transplantation

P1 Development and validation of an interpretable machine learning model for predicting 30-day postoperative mortality in lung transplant recipients with pneumoconiosis in China
Jingyu Chen (Hangzhou, China)

Graft allocation: same goal, different system

P2 Four decades of heart-lung transplantation for end-stage pulmonary hypertension: Evolution of indications and outcomes in a single-center experience
Camille Bonte (Le Plessis-Robinson, France)

P3 Structural determinants of regional lung transplant listing rates in metropolitan France: A national ecological panel study
Kinan El Husseini (Paris, France)



P4 Beyond trust: Implementation of urinary cotinine testing in lung transplant candidate evaluation
Merel Hellemons (Rotterdam, The Netherlands)

P5 The burden of coronary artery disease in lung transplant candidates
Valeria Rossetti (Milan, Italy)

P6 Lung transplantation in recipients aged $\geq$ 70 years: A single-center experience
Rene Novysedlak (Prague, Czech Republic)

P7 Pre-transplant metabolic phenotype predicts long-term survival after lung transplantation
Zsöfia Rosselli (Zürich, Switzerland)

Graft dysfunction: new definition and molecular signature

P8 Research priorities in chronic lung allograft dysfunction: A machine learning-assisted bibliometric analysis
Kinan El Hussein (Paris, France)

P9 Recurrent graft failure after pediatric lung transplantation saved by anakinra therapy after diagnosis of autoinflammation with a likely pathogenic NLRP12 variant
Sophia Pallenberg (Hannover, Deutschland)

P10 Immature neutrophils as a marker of PGD and prolonged ICU stay in lung transplant recipients
Berber Zweers (Utrecht, The Netherlands)

New paradigm for organ preservation

P11 Ex-vivo lung perfusion in Vienna: Reflections on 15 years of clinical application
Panja Maria Boehm (Vienna, Austria)

P12 Extended EVLP model integrating subnormothermic perfusion enhances the effects of thermal reconditioning on damaged donor lungs
Roumen Parapanov (Epalinges, Switzerland)

P13 Improved early lung transplant outcomes with extended ischemia times using a 10°C preservation method: A retrospective cohort study
Zitao Wang (Wuxi, China)

What is the future of lung transplantation

P14 Initiation of a heart-lung transplantation program in an emerging country: Organizational, cultural, and educational challenges
Mouad Gourt (Errachidia, Morocco)

P15 Hybrid venoarterial extracorporeal membrane oxygenation circuit for lung transplantation as transition from conventional cardiopulmonary bypass; single centre experience
Maksym Kovzel (Cambridge, UK)

P16 Lung surgery in lung transplant recipients: A prognostic bicenter study
Giacomo Maruca (Milan, Italy)

P17 Management of bilateral lung transplantation in a recipients with mitral valve replacement
Anna Niroomand (New York, USA)

P18 Can CT-based esophageal markers predict outcomes after lung transplantation in connective tissue diseases?
Pauline Pradère (Le Plessis-Robinson, France)

P19 "Lost in transition" - A single-center cohort analysis of long-term outcomes in pediatric lung transplant patients reaching adult age
Susanne Simon (Hannover, Deutschland)

Aknowledgments

Platinum sponsor

sanofi

Gold sponsor

 **Therakos**

Silver sponsors

 **CareDx**

 **Takeda**

XVIVO

Sponsor

 **okeiro**

Exhibitors

GRIFOLS

 **MicroGenDX**
qPCR + NGS DNA DIAGNOSTICS

PARAGONIX
A GETINGE COMPANY



Endorsed by

